Mei-Mei Zheng

Mei-Mei Zheng

Auto-generated profile, based on publicly available information

Mei-Mei Zheng

Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2025 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
LTLi bo Tang
Li bo Tang
YPYing-Long Peng
Ying-Long Peng
JCJi Chen
Ji Chen
JLJia-Ting Li
Jia-Ting Li
MZMei-Mei Zheng
Mei-Mei Zheng
QZQing Zhou
Qing Zhou

27 February 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MZMei-Mei Zheng
Mei-Mei Zheng
QZQing Zhou
Qing Zhou
HCHua-Jun Chen
Hua-Jun Chen
BJBen-Yuan Jiang
Ben-Yuan Jiang
LTLi bo Tang
Li bo Tang
YWYI-LONG WU
YI-LONG WU

28 November 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
YLYang-Si Li
Yang-Si Li
WLWenpu Lai
Wenpu Lai
KYKai Yin
Kai Yin
HTHai-Yan Tu
Hai-Yan Tu
LLLiang Li
Liang Li
YWYI-LONG WU
YI-LONG WU
Background: Brain metastases (BrM) in non-small cell lung cancer (NSCLC) present a significant challenge due to poor prognosis. While immune checkpoint inhibitors (ICIs) have been standard treatments for NSCLC, their efficacy in BrM is variable, emphasizing the urgent need for predictive biomarkers and fundamental mechanisms. Methods: Patients with NSCLC and BrM planning to receive ICI therapy were enrolled in the prospective cohort, dynamic cerebrospinal fluid (CSF) samples (n=20) were collected through lumbar puncture and used for single-cell RNA sequencing (scRNA-seq), and BrM tumors were collected if they have the indications of surgery, with integrating scRNA-seq data from external database (total n=20). Three independent cohorts underwent flow cytometry (n=8), proteomics analysis (n=31), and multiplex immunohistochemistry (n=25) for validation. Results: Our study provided a high-resolution atlas of cellular dynamics in the CSF and BrM during ICI therapy in patients with NSCLC and BrM. Notably, we identified a key immune cell subset, CD4 + PDCD1 + CXCR6 + T cells, as a positive predictor of ICI intracranial tumor responses, which presented highly functional and transcriptomic similarities in both CSF and BrM tumor environment. Moreover, CXCR6 could serve as a specific marker for CD4 + PDCD1 + T cells linked to ICI response. Further, we revealed that the novel cluster of CD4 + PDCD1 + CXCR6 + T cells was closely associated with lymphocyte activation and aggregation in CSF and BrM of ICI responders, and classical dendritic cells of ICI responders interacted with CD4 + PDCD1 + CXCR6 + T cells for enhanced antigen presentation and inflammatory activation. Conclusion: Our findings revealed critical insights into the immune landscape of NSCLC BrM under ICI therapy, highlighting CD4 + PDCD1 + CXCR6 + T cells in CSF as a promising biomarker and illuminating fundamental mechanisms underlying ICI efficacy.

26 August 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
SLShouheng Lin
Shouheng Lin
KYKai Yin
Kai Yin
MZMei-Mei Zheng
Mei-Mei Zheng
HTHai-Yan Tu
Hai-Yan Tu
WLWanjun Li
Wanjun Li
PLPeng Li
Peng Li
The prognosis of non–small cell lung cancer (NSCLC) with leptomeningeal metastasis (LM) is dismal. The regulators of LM progression remain elusive, thus impeding effective clinical intervention. Here, we performed in vivo genome-wide CRISPR-based screens and found that fused in sarcoma (FUS) ablation promoted LM in both PC9 and A549 cells. FUS repressed CD36 expression by directly interacting with and destabilizing PPARA ( peroxisome proliferator–activated receptor α) messenger RNA. CD36 augmented fatty acid uptake and oxidative phosphorylation in NSCLC cells. Matrix metallopeptidase 2 (MMP2) was up-regulated through CD36-mediated fatty acid metabolism, which enabled NSCLC cells to disrupt the endothelial barrier. FUS-deficient NSCLC cells increased the expression of neuroendocrine differentiation (NED)–related markers, including SRY-box transcription factor 2 (SOX2), microtubule-associated protein 2 (MAP2), enolase 2 (NSE), and synaptophysin (SYP). They also exhibited neurite-like extensions and expanded in cerebrospinal fluid–supplemented medium in a CD36-dependent manner. Mechanistically, fatty acid uptake increased acetyl-coenzyme A and H3K27ac modifications to promote the expression of NED signature genes and MMP2 in NSCLC cells. Genetic or pharmacological inhibition of CD36 or inhibition of NED-related markers in NSCLC cells hindered LM and prolonged survival in mice. In patients with NSCLC, down-regulation of FUS or up-regulation of CD36 or SYP was associated with progression to LM. Thus, CD36-mediated fatty acid metabolism and NED signature are crucial for progression to LM in NSCLC, highlighting CD36 as a promising therapeutic target to limit the progression of LM.